|Ritonavir||Protease inhibitor (pharmacokinetic booster)|
Atazanavir/ritonavir (ATV/r) is a combination medication used in the treatment of HIV/AIDS. It combines atazanavir and ritonavir. It may be used instead of lopinavir/ritonavir. It is taken by mouth.
Side effects are generally minimal. They may include abdominal pain, diarrhea, yellowish skin, muscle pains, and headache. Greater care should be taken in people with underlying liver problems. Use in pregnancy appears to be safe. In the combination atazanavir functions as a protease inhibitor and ritonavir functions to increase levels of atazanavir.
The combination was approved for use in India in 2012 and is pending approval in the US as of 2017. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The average cost per year is 281 USD in the developing world as of 2012.
- "Atazanavir/ritonavir - Mylan Laboratories - AdisInsight". adisinsight.springer.com. Retrieved 29 June 2017.
- "WHO Model List of Essential Medicines Application" (PDF). WHO. Retrieved 29 June 2017.
- "Atazanavir/Ritonavir in Pregnancy". hivinsite.ucsf.edu. Retrieved 10 December 2017.
- "WHO Model List of Essential Medicines (20th List)" (PDF). World Health Organization. March 2017. Retrieved 29 June 2017.